OA13270A - Muscarinic acetylcholine receptor antagonists. - Google Patents

Muscarinic acetylcholine receptor antagonists. Download PDF

Info

Publication number: OA13270A
Authority: OA; OAPI
Prior art keywords: bicyclo; hydroxy; azonia; compound; dimethyl
Prior art date: 2003-10-17

Application number

OA1200600124A

Other languages

English (en)

Inventor

Michael R Palovich

Zehong Wan

Chongjie Zhu

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-17

Filing date

2004-10-15

Publication date

2007-01-31

2004-10-15 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-01-31 Publication of OA13270A publication Critical patent/OA13270A/en

Links

229940121683 Acetylcholine receptor antagonist Drugs 0.000 title abstract description 3
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title abstract description 3
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 claims description 31
102000005962 receptors Human genes 0.000 claims description 12
108020003175 receptors Proteins 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 7
230000003551 muscarinic effect Effects 0.000 claims description 7
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 6
125000001072 heteroaryl group Chemical group 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 5
BUFDXBRKTDFWRN-UHFFFAOYSA-M 2-(8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-ylidene)-1,1-dithiophen-2-ylethanol;iodide Chemical compound [I-].C[N+]1(C)C(C2)CCC1CC2=CC(O)(C=1SC=CC=1)C1=CC=CS1 BUFDXBRKTDFWRN-UHFFFAOYSA-M 0.000 claims description 4
NIFBNIANYCOETB-UHFFFAOYSA-N 8-methyl-n-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-amine Chemical compound CN1C(C2)CCC1CC2NCCC1=CC=CC=C1 NIFBNIANYCOETB-UHFFFAOYSA-N 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
NPVWDHNHELWOAT-UHFFFAOYSA-M 2-(8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-ylidene)-1,1-diphenylethanol;iodide Chemical compound [I-].C[N+]1(C)C(C2)CCC1CC2=CC(O)(C=1C=CC=CC=1)C1=CC=CC=C1 NPVWDHNHELWOAT-UHFFFAOYSA-M 0.000 claims description 2
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
150000001450 anions Chemical class 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
229940077388 benzenesulfonate Drugs 0.000 claims description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
125000003107 substituted aryl group Chemical group 0.000 claims description 2
229940112141 dry powder inhaler Drugs 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
PQZAQCOGMGANAE-UHFFFAOYSA-M 2-benzyl-1-(8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-ylidene)-3-phenylpropan-2-ol;iodide Chemical compound [I-].C[N+]1(C)C(C2)CCC1CC2=CC(O)(CC=1C=CC=CC=1)CC1=CC=CC=C1 PQZAQCOGMGANAE-UHFFFAOYSA-M 0.000 claims 1
206010006458 Bronchitis chronic Diseases 0.000 claims 1
206010014561 Emphysema Diseases 0.000 claims 1
206010061876 Obstruction Diseases 0.000 claims 1
JVMKZHYSVDTFED-UHFFFAOYSA-N bicyclo[3.2.1]octane hydroiodide Chemical compound I.C1C2CCC1CCC2 JVMKZHYSVDTFED-UHFFFAOYSA-N 0.000 claims 1
206010006451 bronchitis Diseases 0.000 claims 1
208000007451 chronic bronchitis Diseases 0.000 claims 1
229940071648 metered dose inhaler Drugs 0.000 claims 1
208000005069 pulmonary fibrosis Diseases 0.000 claims 1
238000000034 method Methods 0.000 abstract description 10
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
101150041968 CDC13 gene Proteins 0.000 description 5
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 4
-1 ammonium cations Chemical class 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
AMJRSUWJSRKGNO-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O AMJRSUWJSRKGNO-UHFFFAOYSA-N 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
229960002329 methacholine Drugs 0.000 description 3
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
125000004446 heteroarylalkyl group Chemical group 0.000 description 2
125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000243 solution Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
102000007527 Autoreceptors Human genes 0.000 description 1
108010071131 Autoreceptors Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000036428 airway hyperreactivity Effects 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001022 anti-muscarinic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001669 calcium Chemical class 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
210000002932 cholinergic neuron Anatomy 0.000 description 1
DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000009989 contractile response Effects 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000003269 fluorescent indicator Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000005553 heteroaryloxy group Chemical group 0.000 description 1
230000035873 hypermotility Effects 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
SNHOZPMHMQQMNI-UHFFFAOYSA-N lithium;2h-thiophen-2-ide Chemical compound [Li+].C=1C=[C-]SC=1 SNHOZPMHMQQMNI-UHFFFAOYSA-N 0.000 description 1
IWCVDCOJSPWGRW-UHFFFAOYSA-M magnesium;benzene;chloride Chemical compound [Mg+2].[Cl-].C1=CC=[C-]C=C1 IWCVDCOJSPWGRW-UHFFFAOYSA-M 0.000 description 1
SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
OXBRQNQURPPYHW-UHFFFAOYSA-N methyl 2-(8-methyl-8-azabicyclo[3.2.1]octan-3-ylidene)acetate Chemical compound C1C(=CC(=O)OC)CC2CCC1N2C OXBRQNQURPPYHW-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
230000007384 vagal nerve stimulation Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pulmonology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200600124A 2003-10-17 2004-10-15 Muscarinic acetylcholine receptor antagonists. OA13270A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US51216103P	2003-10-17	2003-10-17

Publications (1)

Publication Number	Publication Date
OA13270A true OA13270A (en)	2007-01-31

Family

ID=34465319

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200600124A OA13270A (en)	2003-10-17	2004-10-15	Muscarinic acetylcholine receptor antagonists.

Country Status (22)

Country	Link
US (1)	US7507747B2 (fr)
EP (1)	EP1677796A4 (fr)
JP (1)	JP2007509061A (fr)
CN (1)	CN1897947A (fr)
AP (1)	AP2006003575A0 (fr)
AR (1)	AR046114A1 (fr)
AU (1)	AU2004281167A1 (fr)
BR (1)	BRPI0415281A (fr)
CA (1)	CA2542636A1 (fr)
EA (1)	EA200600787A1 (fr)
EC (1)	ECSP066486A (fr)
IL (1)	IL174846A0 (fr)
IS (1)	IS8440A (fr)
MA (1)	MA28109A1 (fr)
MX (1)	MXPA06004242A (fr)
NO (1)	NO20062071L (fr)
OA (1)	OA13270A (fr)
PE (1)	PE20050442A1 (fr)
TW (1)	TW200528448A (fr)
UY (1)	UY28567A1 (fr)
WO (1)	WO2005037224A2 (fr)
ZA (1)	ZA200602783B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200519108A (en) *	2003-07-17	2005-06-16	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
TW200524577A (en) *	2003-11-04	2005-08-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (fr) *	2004-03-11	2005-09-22	Glaxo Group Limited	Nouveaux antagonistes du recepteur de l'acetylcholine muscarinique m3
WO2005095407A1 (fr) *	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
WO2005094251A2 (fr) *	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur muscarinique a l'acetylcholine m3
AR050902A1 (es)	2004-04-27	2006-12-06	Glaxo Group Ltd	Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (fr) *	2004-05-13	2010-05-26	Glaxo Group Ltd	Domaine de l'invention antagonistes récepteurs d'acétyle choline muscarinique
JP2008520579A (ja) *	2004-11-15	2008-06-19	グラクソグループリミテッド	新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937267A4 (fr) *	2005-08-02	2009-08-26	Glaxo Group Ltd	Antagonistes des recepteurs de l' acetylcholine muscarinique m3
US7767691B2 (en) *	2005-08-18	2010-08-03	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
AR070564A1 (es)	2008-02-06	2010-04-21	Glaxo Group Ltd	Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
UY31637A1 (es)	2008-02-06	2009-08-03		Farmacoforos duales-antagonistas muscarinicos de pde4
CL2009000249A1 (es)	2008-02-06	2009-09-11	Glaxo Group Ltd	Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
WO2010094643A1 (fr)	2009-02-17	2010-08-26	Glaxo Group Limited	Dérivés de quinoline et applications associées dans la rhinite et l'urticaire

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2800481A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) *	1967-06-08	1972-04-25	Siemens Ag	Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
CY1308A (en)	1979-12-06	1985-12-06	Glaxo Group Ltd	Device for dispensing medicaments
EP0069715B1 (fr)	1981-07-08	1986-11-05	Aktiebolaget Draco	Inhalateur de poudre
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
DK172541B1 (da)	1982-10-08	1998-12-07	Glaxo Group Ltd	Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
CH667657A5 (de) *	1985-01-07	1988-10-31	Sandoz Ag	Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
AU591152B2 (en)	1985-07-30	1989-11-30	Glaxo Group Limited	Devices for administering medicaments to patients
IT1204826B (it)	1986-03-04	1989-03-10	Chiesi Farma Spa	Composizioni farmaceutiche per inalazione
GB9004781D0 (en) *	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
US5780466A (en) *	1995-01-30	1998-07-14	Sanofi	Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
WO1998024788A1 (fr) *	1996-12-02	1998-06-11	Georgetown University	Derives tropane et procede de synthese
US6248752B1 (en) *	1998-02-27	2001-06-19	Charles Duane Smith	Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) *	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) *	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6552036B2 (en) *	2000-03-03	2003-04-22	Ortho-Mcneil Pharmaceutical, Inc.	3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
RU2004110717A (ru) *	2001-10-17	2005-10-20	Юсиби, С.А. (Be)	Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
US6696462B2 (en) *	2002-01-31	2004-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
UY27927A1 (es) *	2002-08-06	2003-12-31	Glaxo Group Ltd	Antagonistas del receptor muscarínico m3 de acetilcolina
WO2004091482A2 (fr) *	2003-04-07	2004-10-28	Glaxo Group Limited	Antagonistes du recepteur muscarinique m3 de l'acetylcholine
PE20050711A1 (es) *	2003-07-17	2005-09-10	Glaxo Group Ltd	Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
PE20050327A1 (es) *	2003-07-17	2005-06-08	Glaxo Group Ltd	Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) *	2003-07-17	2005-06-16	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
CN101230061A (zh) *	2003-10-14	2008-07-30	葛兰素集团有限公司	蕈毒碱性乙酰胆碱受体拮抗剂
TW200524577A (en) *	2003-11-04	2005-08-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
ES2329586T3 (es) *	2003-11-21	2009-11-27	Theravance, Inc.	Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
UY28645A1 (es) *	2003-12-03	2005-06-30	Glaxo Group Ltd	Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
PE20050861A1 (es) *	2003-12-03	2005-12-10	Glaxo Group Ltd	Derivados de sales ciclicas de amonio cuaternario como antagonistas del receptor muscarinico de acetilcolina
US20070185088A1 (en) *	2004-03-17	2007-08-09	Jakob Busch-Petersen	M3 muscarinic acetylchoine receptor antagonists
WO2005094251A2 (fr) *	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur muscarinique a l'acetylcholine m3
WO2005095407A1 (fr) *	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
US20070185090A1 (en) *	2004-03-17	2007-08-09	Jakob Busch-Petersen	Muscarinic acetylchoine receptor antagonists
AR050902A1 (es) *	2004-04-27	2006-12-06	Glaxo Group Ltd	Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (fr) *	2004-05-13	2010-05-26	Glaxo Group Ltd	Domaine de l'invention antagonistes récepteurs d'acétyle choline muscarinique
TW200606161A (en) *	2004-05-28	2006-02-16	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
JP2008520579A (ja)	2004-11-15	2008-06-19	グラクソグループリミテッド	新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2006055503A2 (fr)	2004-11-15	2006-05-26	Glaxo Group Limited	Nouveaux antagonistes du recepteur d'acetylcholine muscarinique m3
PE20061162A1 (es)	2004-12-06	2006-10-14	Smithkline Beecham Corp	Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es)	2004-12-06	2006-10-08	Smithkline Beecham Corp	Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (fr)	2004-12-13	2006-06-22	Glaxo Group Limited	Nouveaux antagonistes du recepteur muscarinique de l'acetylcholine
WO2006065755A2 (fr)	2004-12-13	2006-06-22	Glaxo Group Limited	Sels d'ammonium quaternaire d'amines heteroaromatiques fusionnees utilises comme nouveaux antagonistes du recepteur de l'acetylcholine muscarinique
WO2007018514A1 (fr)	2005-07-28	2007-02-15	Glaxo Group Limited	Nouveaux antagonistes récepteurs d’acétylcholine muscarinique m3
WO2007018508A1 (fr)	2005-07-28	2007-02-15	Glaxo Group Limited	Nouveaux antagonistes du récepteur muscarinique m3 de l’acétylcholine

2004
- 2004-10-15 MX MXPA06004242A patent/MXPA06004242A/es not_active Application Discontinuation
- 2004-10-15 BR BRPI0415281-6A patent/BRPI0415281A/pt not_active Application Discontinuation
- 2004-10-15 AP AP2006003575A patent/AP2006003575A0/xx unknown
- 2004-10-15 TW TW093131251A patent/TW200528448A/zh unknown
- 2004-10-15 AU AU2004281167A patent/AU2004281167A1/en not_active Abandoned
- 2004-10-15 OA OA1200600124A patent/OA13270A/en unknown
- 2004-10-15 PE PE2004001004A patent/PE20050442A1/es not_active Application Discontinuation
- 2004-10-15 CA CA002542636A patent/CA2542636A1/fr not_active Abandoned
- 2004-10-15 CN CNA2004800380467A patent/CN1897947A/zh active Pending
- 2004-10-15 EP EP04795406A patent/EP1677796A4/fr not_active Withdrawn
- 2004-10-15 AR ARP040103734A patent/AR046114A1/es not_active Application Discontinuation
- 2004-10-15 US US10/575,837 patent/US7507747B2/en not_active Expired - Fee Related
- 2004-10-15 JP JP2006535384A patent/JP2007509061A/ja active Pending
- 2004-10-15 EA EA200600787A patent/EA200600787A1/ru unknown
- 2004-10-15 UY UY28567A patent/UY28567A1/es not_active Application Discontinuation
- 2004-10-15 WO PCT/US2004/034234 patent/WO2005037224A2/fr not_active Ceased
2006
- 2006-04-05 ZA ZA200602783A patent/ZA200602783B/xx unknown
- 2006-04-06 EC EC2006006486A patent/ECSP066486A/es unknown
- 2006-04-06 IL IL174846A patent/IL174846A0/en unknown
- 2006-04-25 MA MA28963A patent/MA28109A1/fr unknown
- 2006-05-05 IS IS8440A patent/IS8440A/is unknown
- 2006-05-08 NO NO20062071A patent/NO20062071L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BRPI0415281A (pt)	2006-12-19
CN1897947A (zh)	2007-01-17
TW200528448A (en)	2005-09-01
ZA200602783B (en)	2007-11-28
NO20062071L (no)	2006-05-08
EP1677796A2 (fr)	2006-07-12
AP2006003575A0 (en)	2006-04-30
WO2005037224A2 (fr)	2005-04-28
IL174846A0 (en)	2006-08-20
PE20050442A1 (es)	2005-07-09
US20070135478A1 (en)	2007-06-14
AR046114A1 (es)	2005-11-23
EA200600787A1 (ru)	2006-08-25
MXPA06004242A (es)	2006-06-28
US7507747B2 (en)	2009-03-24
AU2004281167A1 (en)	2005-04-28
WO2005037224A3 (fr)	2005-06-23
EP1677796A4 (fr)	2006-12-27
CA2542636A1 (fr)	2005-04-28
UY28567A1 (es)	2005-05-31
JP2007509061A (ja)	2007-04-12
IS8440A (is)	2006-05-05
MA28109A1 (fr)	2006-08-01
ECSP066486A (es)	2006-10-10

Publication	Publication Date	Title
OA13316A (en)	2007-04-13	Muscarinic acetylcholine receptor antagonists.
US7507747B2 (en)	2009-03-24	Muscarinic acetylcholine receptor antagonists
TW200524577A (en)	2005-08-01	Muscarinic acetylcholine receptor antagonists
JP2006502180A (ja)	2006-01-19	５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
AU2011268373B2 (en)	2014-05-22	Piperidinyl compound as a modulator of chemokine receptor activity
EP2121688A1 (fr)	2009-11-25	Dérivés hétérocycliques en tant que récepteurs muscariniques m3
WO2006065788A2 (fr)	2006-06-22	Nouveaux antagonistes du recepteur muscarinique de l'acetylcholine
PT1960398E (pt)	2010-11-26	Derivados de ácido e de ésteres arilacéticos e suas utilizações como anti-inflamatórios
JPH0761968A (ja)	1995-03-07	ヘテロ環を含有する尿素誘導体
AU2018215466B2 (en)	2022-03-10	Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof
AU2007203077B2 (en)	2010-07-22	Muscarinic acetylcholine receptor antagonists
KR20070017965A (ko)	2007-02-13	무스카린성 아세틸콜린 수용체 길항제
WO2025184322A1 (fr)	2025-09-04	Composés hétérocycliques et leurs procédés d'utilisation